Rights and permissions
About this article
Cite this article
Q-TWiST favours epirubicin-containing regimen in breast cancer. Pharmacoecon. Outcomes News 472, 13 (2005). https://doi.org/10.2165/00151234-200504720-00037
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504720-00037